Leadership Overview
Bristol-Myers Squibb has 10 executives leading key functions including operations, cell therapy development, technology, finance, and medical affairs.
Driven by a commitment to scientific innovation, Bristol-Myers Squibb is dedicated to discovering, developing, and delivering transformative medicines that address serious unmet patient needs across oncology, immunology, and cardiovascular disease.
Driven by a commitment to scientific innovation, Bristol-Myers Squibb is dedicated to discovering, developing, and delivering transformative medicines that address serious unmet patient needs across oncology, immunology, and cardiovascular disease.
Leadership Roles at Bristol-Myers Squibb
Bud Glogovac - Director, Finance (Country & Chief Financial Officer
Bud Glogovac, the Director, Finance (Country & Chief Financial Officer at Bristol-Myers Squibb, oversees financial operations and strategic planning for specific country markets and contributes to broader financial leadership. This role involves managing financial performance, budgeting, forecasting, and ensuring fiscal responsibility across designated regions. Bud Glogovac provides critical financial insights to support business decisions, optimize resource allocation, and drive profitable growth. By ensuring sound financial management, Bud Glogovac supports the company's investment in research and development and its commitment to delivering innovative medicines. This finance leadership position is integral to maintaining the financial health and strategic direction of Bristol-Myers Squibb's global operations.
Tomas Bohman - Global Chief Financial Officer, Research & Senior VP, Development, Finance
Tomas Bohman, the Global Chief Financial Officer, Research & Senior VP, Development, Finance at Bristol-Myers Squibb, directs financial strategy and operations for the company's extensive research and development endeavors. This pivotal role ensures robust financial planning, resource allocation, and fiscal oversight for all R&D activities, including the discovery and clinical progression of new medicines. Tomas Bohman provides critical financial guidance that enables strategic investments in cutting-edge science and therapeutic innovation across oncology, immunology, and cardiovascular disease. By managing the financial aspects of development, Tomas Bohman directly supports the company's mission to address serious unmet patient needs. This leadership position is fundamental to sustaining Bristol-Myers Squibb's commitment to scientific advancement and long-term growth.
Jessica Snow - Chief Operating Officer
Jessica Snow, the Chief Operating Officer at Bristol-Myers Squibb, directs global operational strategies and execution across the organization. Overseeing manufacturing, supply chain, and operational excellence initiatives, Jessica Snow ensures the efficient delivery of critical medicines to patients worldwide. This leadership role involves optimizing production processes, managing complex global logistics, and driving continuous improvement across all operational facets. By enhancing supply chain resilience and manufacturing scalability, Jessica Snow directly supports the company's mission to address serious patient needs in oncology, cardiovascular disease, and immunology. The Chief Operating Officer's focus extends to fostering a culture of safety and quality, ensuring adherence to stringent regulatory standards across all global facilities. This strategic oversight guarantees that Bristol-Myers Squibb can reliably meet market demand for its innovative therapies.
Nicole Costa - Cell Therapy Development & Operations Chief of Staff
Nicole Costa, the Cell Therapy Development & Operations Chief of Staff at Bristol-Myers Squibb, provides strategic support and operational coordination for the cell therapy division. This role involves aligning development timelines, operational readiness, and cross-functional collaboration to accelerate the advancement of innovative cell therapies. Nicole Costa ensures seamless integration between research, clinical development, and manufacturing operations for these complex treatments. By streamlining communication and resource allocation, Nicole Costa drives efficiency and supports the rapid progression of cell therapy candidates through the development pipeline. The Chief of Staff's efforts are critical in translating scientific breakthroughs into tangible treatment options for patients facing challenging diseases like cancer. This position demands a deep understanding of biopharmaceutical operations and a commitment to advancing cutting-edge therapeutic modalities.
Joshua Sugrim - Manager, Chief Technology Officer MSAT Process Validation - CAR T Cell Therapy
Joshua Sugrim, the Manager, Chief Technology Officer MSAT Process Validation - CAR T Cell Therapy at Bristol-Myers Squibb, leads critical process validation activities for CAR T cell therapies. This role ensures the robustness, reproducibility, and regulatory compliance of manufacturing processes for these advanced treatments. Joshua Sugrim oversees the validation lifecycle, from protocol development to execution and reporting, guaranteeing that all processes meet stringent quality and safety standards. By meticulously validating manufacturing methods, Joshua Sugrim directly contributes to the reliable production of life-saving cell therapies. The Manager's expertise is essential in navigating the complex technical requirements of cell therapy manufacturing and ensuring patient access to these innovative oncology treatments. This position requires a profound understanding of bioprocess engineering and quality assurance principles.
Kimberly Kam - Senior Specialist, Chief Technology Officer MSAT Process Validation Engineer II
Kimberly Kam, the Senior Specialist, Chief Technology Officer MSAT Process Validation Engineer II at Bristol-Myers Squibb, executes and supports process validation initiatives within the Manufacturing Science and Technology (MSAT) group. This role focuses on ensuring that manufacturing processes for biopharmaceuticals are consistently capable of producing products meeting predetermined specifications and quality attributes. Kimberly Kam contributes to the development and implementation of validation strategies, data analysis, and documentation required for regulatory submissions. By ensuring the integrity of process validation, Kimberly Kam upholds the company's commitment to delivering safe and effective medications. This engineering position is vital for maintaining the high standards of quality and compliance necessary in pharmaceutical manufacturing, particularly for complex therapeutic areas.
Benjamin Kingscott - Manager, Chief Technology Officer Plant Engineering
Benjamin Kingscott, the Manager, Chief Technology Officer Plant Engineering at Bristol-Myers Squibb, directs plant engineering operations and capital project execution. This leadership position ensures that manufacturing facilities are designed, maintained, and upgraded to support the efficient and compliant production of pharmaceutical products. Benjamin Kingscott oversees teams responsible for facility infrastructure, equipment reliability, and the implementation of new technologies to enhance operational capabilities. By managing plant engineering functions, Benjamin Kingscott directly supports the company's ability to scale production and maintain a robust supply chain for its diverse medication portfolio. This role is critical in ensuring that Bristol-Myers Squibb's global manufacturing sites operate at peak performance and adhere to all safety and environmental regulations.
Amy Silverstein - Chief of Staff To Chief Medical Officer, Head of Development
Amy Silverstein, the Chief of Staff To Chief Medical Officer, Head of Development at Bristol-Myers Squibb, provides strategic operational support and facilitates key initiatives within the medical and development functions. This role ensures alignment across complex projects, enhances communication channels, and drives the execution of strategic priorities set by the Chief Medical Officer. Amy Silverstein coordinates cross-functional efforts, manages critical timelines, and supports the advancement of the company's drug development pipeline. By optimizing the operational effectiveness of the development team, Amy Silverstein directly contributes to bringing novel therapies to patients faster. This position requires a comprehensive understanding of pharmaceutical development and a commitment to advancing medical science.
Debra Golding - Senior Executive Associate, Chief of Staff and Compliance
Debra Golding, the Senior Executive Associate, Chief of Staff and Compliance at Bristol-Myers Squibb, provides essential support to executive leadership, focusing on operational efficiency and adherence to compliance standards. This role involves coordinating key projects, managing administrative functions, and ensuring that all activities align with regulatory requirements and company policies. Debra Golding facilitates effective communication and workflow between different departments, contributing to the smooth operation of executive-level initiatives. By upholding compliance and supporting strategic operations, Debra Golding plays a crucial part in maintaining the integrity and effectiveness of Bristol-Myers Squibb's business practices. This position is vital for ensuring that the company operates ethically and efficiently across its global footprint.
Andreia Pierce - Head Ed, Oncology Commercialization S & O To Chief of Staff & Senior VP
Andreia Pierce, the Head Ed, Oncology Commercialization S & O To Chief of Staff & Senior VP at Bristol-Myers Squibb, leads strategic initiatives within oncology commercialization, providing critical support to the Chief of Staff and Senior VP. This role focuses on enhancing market access, optimizing commercial strategies, and ensuring effective go-to-market execution for oncology therapies. Andreia Pierce drives operational excellence in commercial functions, aligning sales, marketing, and medical affairs efforts to maximize patient reach and therapeutic impact. By developing and implementing robust commercial plans, Andreia Pierce directly contributes to the success of Bristol-Myers Squibb's oncology portfolio. This leadership position is instrumental in translating scientific advancements into accessible treatments for cancer patients worldwide.
Explore Leadership Teams in Manufacturing
Fresenius Kabi, a subsidiary of Fresenius, is a global health care company that specializes in medicines and technologies for infusion, transfusion, and clinical nutrition. Fresenius Kabi is headquartered in Bad Homburg, Germany with locations around the world.
Company Leadership SM
AK
KL
Roche is a global pioneer in pharmaceuticals and diagnostics, dedicated to advancing science to improve people's lives through innovative healthcare solutions. The Swiss-based company operates through two primary divisions: Pharmaceuticals and Diagnostics, making it one of the few healthcare companies with leading positions in both areas. Roche's pharmaceutical division focuses on developing and manufacturing prescription medicines across major therapeutic areas including oncology, immunology, infectious diseases, ophthalmology, and diseases of the central nervous system. The diagnostics division provides a comprehensive range of products and services for early detection, prevention, diagnosis, and management of diseases, spanning laboratory diagnostics, tissue diagnostics, and diabetes care. Roche is committed to personalized healthcare, pioneering the development of targeted therapies and companion diagnostics that enable treatment decisions tailored to individual patients. The company invests heavily in research and development, maintaining a robust pipeline of innovative medicines and diagnostic solutions while collaborating with academic institutions, biotechnology companies, and healthcare partners worldwide. Headquartered in Basel, Switzerland, Roche operates globally with a presence in numerous countries, employing a diverse workforce of scientists, researchers, healthcare professionals, and business experts dedicated to transforming patient care and making a meaningful difference in the fight against serious diseases.
Company Leadership TH
LA
RL
Md
AstraZeneca focuses on the discovery, development, and commercialization of prescription medicines in Oncology and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. AstraZeneca is based in the United Kingdom.
Company Leadership KO
JZ
Hetero is a global pharmaceutical company founded in 1993 and headquartered in India with operations across Asia, Europe, North America, South America, Africa, and the Middle East. The company specializes in manufacturing generic pharmaceuticals and is recognized as a major producer of anti-retroviral medications for HIV/AIDS treatment. Hetero develops and manufactures a wide range of pharmaceutical products while maintaining research facilities and production centers worldwide.
Company Leadership VS
KS
Frequently Asked Questions Regarding Bristol-Myers Squibb Top Executives and Leadership Team
